Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.

National Institute of Public Health, Oslo, Norway.
Journal of Clinical Microbiology (Impact Factor: 4.23). 09/1988; 26(8):1543-8.
Source: PubMed

ABSTRACT Antibody responses of adult volunteers given a vaccine containing meningococcal capsular polysaccharides (serogroups A, C, Y, and W-135) noncovalently complexed with serotype 2b:P1.2 and 15:P1.16 outer membrane proteins have been studied. Sera were analyzed by enzyme-linked immunosorbent assay methods for immunoglobulin G (IgG), IgM, and IgA antibodies and for bactericidal activities against the homologous strains. The vaccination was performed as a double-blind experiment with 47 volunteers, of whom 23 received the protein-polysaccharide vaccine and 24 received the control preparation containing the polysaccharides only. Ten additional persons volunteered for the protein-polysaccharide vaccine. Before vaccination, carriers of meningococci had significantly higher levels of specific IgG and IgA and also higher bactericidal activities than noncarriers. At 2 weeks postvaccination we found significant IgG and bactericidal antibody responses against both the 2b:P1.2 and 15:P1.16 strains in about 70% of the protein-polysaccharide vaccinees. The immune response induced by disease was compared with that induced by vaccination by analyzing paired sera from 13 survivors of serogroup B serotype 15 meningococcal disease. We found that the mean specific IgG level in acute-phase sera was lower than average in prevaccination sera from the vaccinees but similar to that of healthy noncarriers before vaccination. The convalescent-phase sera showed IgG responses similar to those of the vaccinees, but the IgM response to disease was significantly higher than after vaccination. The immune response to disease caused by serogroup B serotype 15 meningococci was found by enzyme-linked immunosorbent assay analysis to be about the same with outer-membrane antigens from a serotype 2b strain as it was with antigens from a serotype 15 strain.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We havedetermined theamountsofspecific anti-class 1outer membraneprotein antibodies inserafrom25 patients during thecourse ofsystemic meningococcal disease, using purified class 1protein asthesensitizing antigen inanenzyme-linked immunosorbent assay. Theclass 1protein wasobtained fromavariant ofstrain 44/76 (B:15:P1.7,16) lacking class 3andclass 4outermembraneproteins. Specific anti-class 1(serosubtype P1.7,16) outermembraneprotein immunoglobulin G (IgG)antibody levels increased significantly in12 patients (12of25;48%),regardless oftheserotype oftheinfecting strain, indicating thattheantibodies reacted inpartwithepitopes notdetermined bythemonoclonal antibodies usedforserotyping. Mostpatients hadlow levels ofanti-class 1IgGantibodies during theacute illness. Theantibody levels peaked during thesecond week ofdisease andreturned tonearbaseline levels inseracollected 6weeksto12monthsafter theonsetofthe disease. Themajority ofthespecific anti-class 1IgGantibodies boundtosurface-exposed epitopes onwhole bacteria andbelonged totheIgGlandIgG3subclasses. Anti-class 1IgAandIgMantibodies werenotdetected inanyofthepatient sera. Prior todisease, sevenpatients hadbeenimmunized withameningococcal outer membranevesicle vaccine developed fromstrain 44/76(P1.7,16). Noneofthesepatients wasinfected with meningococcal strains containing class 1protein homologous orpartly homologous tothatofthevaccine strain, indicating serosubtype-specific protection. Thehighest anti-class 1IgGantibody peaklevels wereseen inimmunized patients infected withstrains ofheterologous serotype, suggesting ananamnestic response. However, these patients werenotprotected frommeningococcal disease after immunization.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tiivistelmä. Diss. -- Helsingin yliopisto.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To elucidate critical components of protective immune responses induced during the natural course of serogroup A meningococcal disease, we studied acute-, early-convalescent-, and late-convalescent-phase sera from Ethiopian patients during outbreaks in 2002 to 2003. Sera were obtained from laboratory-confirmed patients positive for serogroup A sequence type 7 (ST-7) meningococci (A:4/21:P1.20,9) (n = 71) and from Ethiopian controls (n = 113). The sera were analyzed using an enzyme-linked immunosorbent assay to measure levels of immunoglobulin G (IgG) against serogroup A polysaccharide (APS) and outer membrane vesicles (OMVs) and for serum bactericidal activity (SBA) using both rabbit and human complement sources. Despite relatively high SBA titers and high levels of IgG against APS and OMVs in acute-phase patient sera, significant increases were seen in the early convalescent phase. Antibody concentrations returned to acute-phase levels in the late convalescent phase. Considering all patients' sera, a significant but low correlation (r = 0.46) was observed between SBA with rabbit complement (rSBA) using an ST-5 reference strain and SBA with human complement (hSBA) using an ST-7 strain from Ethiopia. While rSBA demonstrated a significant linear relation with IgG against APS, hSBA demonstrated significant linear relationships with IgG against both APS and OMV. This study indicates that antibodies against both outer membrane proteins and APS may be important in providing the protection induced during disease, as measured by hSBA. Therefore, outer membrane proteins could also have a role as components of future meningococcal vaccines for the African meningitis belt.
    Clin Vaccine Immunol. 01/2007; 14(4):451-63.

Full-text (2 Sources)

Available from
Jun 5, 2014